

Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/A8983265F89EN.html

Date: February 2021

Pages: 65

Price: US\$ 125.00 (Single User License)

ID: A8983265F89EN

Abstracts

Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alexion Pharmaceuticals Inc (Alexion) discovers, develops and markets therapies based on complement biology and inhibition for rare diseases. The company's portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. It also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc Key Recent Developments

Feb 04,2021: Alexion reports fourth quarter and full year 2020 results

Jan 12,2021: Alexion **Highlights** commercial, clinical and financial progress at the 39th

annual J.P. Morgan Healthcare Conference

Dec 14,2020: AstraZeneca to acquire biopharmaceutical firm Alexion for \$39bn

Oct 29,2020: Alexion reports third guarter 2020 results

Oct 06,2020: Alexion **Highlights** promising pipeline & distinguished rare disease



capabilities at Virtual Investor Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.



Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

Table of Contents List of Tables List of Figures

SECTION 1 - ABOUT THE COMPANY

Alexion Pharmaceuticals Inc - Key Facts

Alexion Pharmaceuticals Inc - Key Employees

Alexion Pharmaceuticals Inc - Key Employee Biographies

Alexion Pharmaceuticals Inc - Major Products and Services

Alexion Pharmaceuticals Inc - History

Alexion Pharmaceuticals Inc - Company Statement

Alexion Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Alexion Pharmaceuticals Inc - Business Description

Product Category: Andexxa

Overview

Performance

Product Category: Kanuma

Overview

Performance

Product Category: Soliris

Overview

Performance

Product Category: Strensiq

Overview

Performance

Product Category: Ultomiris

Overview

Performance

Geographical Segment: Asia Pacific

Performance



Geographical Segment: Europe

Performance

Geographical Segment: Others

Performance

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: The US

Performance R&D Overview

Alexion Pharmaceuticals Inc - Corporate Strategy

Alexion Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Alexion Pharmaceuticals Inc - Strengths

Alexion Pharmaceuticals Inc - Weaknesses

Alexion Pharmaceuticals Inc - Opportunities

Alexion Pharmaceuticals Inc - Threats

Alexion Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Alexion Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Feb 04, 2021: Alexion reports fourth quarter and full year 2020 results



Jan 12, 2021: Alexion highlights commercial, clinical and financial progress at the 39th annual J.P. Morgan Healthcare Conference

Oct 29, 2020: Alexion reports third quarter 2020 results

Oct 06, 2020: Alexion highlights promising pipeline & distinguished rare disease capabilities at Virtual Investor Day

Aug 25, 2020: Alexion Pharmaceuticals: Departure of directors or certain officer; election of directors

Aug 06, 2020: Alexion announces appointment of first Chief Diversity Officer

Jul 30, 2020: Alexion reports second quarter 2020 results

Jul 02, 2020: Alexion finalizes settlement with the U.S. Securities and Exchange Commission

Jul 02, 2020: SEC charges Alexion Pharmaceuticals with FCPA violations

Jun 17, 2020: Alexion Charitable Foundation announces first rare belonging grants

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Alexion Pharmaceuticals Inc, Key Facts

Alexion Pharmaceuticals Inc, Key Employees

Alexion Pharmaceuticals Inc, Key Employee Biographies

Alexion Pharmaceuticals Inc, Major Products and Services

Alexion Pharmaceuticals Inc, History

Alexion Pharmaceuticals Inc, Subsidiaries

Alexion Pharmaceuticals Inc, Key Competitors

Alexion Pharmaceuticals Inc, Ratios based on current share price

Alexion Pharmaceuticals Inc., Annual Ratios

Alexion Pharmaceuticals Inc, Annual Ratios (Cont...1)

Alexion Pharmaceuticals Inc, Annual Ratios (Cont...2)

Alexion Pharmaceuticals Inc, Interim Ratios

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to

YTD 2021

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to

YTD 2021

Alexion Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Alexion Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Alexion Pharmaceuticals Inc, Ratio Charts

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to

YTD 2021

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Regeneron Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Biogen Inc

Arvinas Inc

Novartis AG

Genzyme Corp

Baxter International Inc

DepYmed Inc

Amgen Inc



I would like to order

Product name: Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/A8983265F89EN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A8983265F89EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
**All fields are required	
Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970